Dermasana™ Active Ingredient Against Staphylococcus aureus
Staphylococcus aureus is a human pathogen that can cause a range of clinically significant infections. Methicillin resistance (MRSA) has occurred in S. aureus by mutation of a penicillin-binding protein, the incidence of which is sharply rising globally. MRSA can cause a range of organ-specific infections, the most common being the skin and subcutaneous tissues, followed by invasive infections like osteomyelitis, meningitis, pneumonia, lung abscess, and empyema. Infective endocarditis caused by MRSA is associated with an increased morbidity and mortality compared to any other organism.
The commonly associated risk factors for MRSA infection are prolonged hospitalization, intensive care admission, recent hospitalization, recent antibiotic use, MRSA colonization, invasive procedures, HIV infection, admission to nursing homes, open wounds, hemodialysis, and discharge with long-term central venous access or long-term indwelling urinary catheter. A higher incidence of MRSA infection is also seen among healthcare workers who come in direct contact with patients infected with this organism.
There is a high unmet medical need for specific but non-antibiotic approaches against Staphylococcus aureus without the risk of inducing antibiotic resistancies and microbiome dysregulation. Even more, highly specific prophylactic decolonization approaches against Stapphylococcus aureus promise a paradigm change in MRSA management.
The active ingredient Dermasana™, which is based on a highly selected Lactobacillus gasseri strain, has been identified in a complex screening procedure as an anti-Staphylococcus aureus active from a large bacterial strain collection. Dermasana™ consists of inactivated, freeze-dried Lactobacillus gasseri cells in a starch matrix and is patent protected.
The Mechanism Of Action Of Dermasana™
The effect of the Dermasana™ bacterium on Staphylococcus aureus is fascinating. Within milliseconds, Staphylococcus aureus firmly adheres to the cell walls of inactivated Dermasana™ bacteria and co-aggregates when brought together in a liquid environment. Lumps of these co-aggregates can be observed under the electron microscope. These co-aggregates can be mechanically removed from affected areas. This effect is highly selective, the active ingredient does not aggregate with commensal skin bacteria. Thus Dermasana™ has no adverse effects on the human skin microbiome.
Since the mechanism of action is based on the bacterial cell wall, we do not need to introduce living bacteria in products. Dermasana™ contains only the bacterial envelopes and does not impose any risks of overcolonization or genetic transfer with the skin or mucosal microbiome.
It is intended to develop prophylactic cosmetical and medical device products against dermal and mucosal Staphylococcus aureus colonization based on the active ingredient Dermasana™.
Based on a significant amount of in vitro evidence regarding the innovative mode of action we are interested in cooperating with interested partners in product development and commercialization in the area of skin care, mucosal care and wound care products.
Dermasana™ is patent protected.